RESEARCH MONOGRAPH · KDC-MN-204

Citalopram

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 3 min read

Our opinion on this compound

80/100

Solid generic SSRI with a QT problem that knocked it back from first-line status

Citalopram has the most boring-good pharmacology in the SSRI class, and we mean that as praise. Lundbeck's Klaus Bogeso group synthesized it in 1972, it was approved in Europe in 1989 and the US in 1998, and for about a decade it was the SSRI prescribers reached for when they wanted predictable serotonergic action with minimal pharmacological complications. Then the FDA QT warning hit in 2011 and the field shifted to escitalopram.

The molecule itself is a racemic mixture of the R and S enantiomers. The S-enantiomer (escitalopram) does essentially all of the SERT inhibition, the R-enantiomer is roughly therapeutically inert but appears to actually antagonize the S-enantiomer's activity at higher concentrations (the so-called allosteric SERT story Lundbeck used to differentiate escitalopram). Half-life is around 35 hours. CYP2C19 is the main metabolizing enzyme, with CYP3A4 secondary.

The 2011 FDA warning came after analysis showing dose-dependent QT prolongation at 60 mg vs 40 mg, with a small but real signal for torsades de pointes in vulnerable populations. The 40 mg cap became 20 mg in patients over 60 or with hepatic impairment or CYP2C19 poor-metabolizer status. That regulatory action effectively made escitalopram the default for the same pharmacological niche, since escitalopram doesn't share the QT signal at typical doses.

What we like is that citalopram is genuinely the cleanest pure SERT inhibitor in the racemic SSRI family, with very little off-target receptor activity compared to paroxetine (anticholinergic) or sertraline (DAT activity). For research that wants to isolate SERT effects from confounding receptor noise, racemic citalopram is a useful tool, especially in animal models where the QT issue doesnt apply.

Clinical efficacy is roughly equivalent to other SSRIs in MDD trials, with the standard discontinuation syndrome that you'd expect from a 35-hour half-life SSRI. Sexual dysfunction is in the typical range. Onset is the standard 2-6 weeks. Everything about it is unremarkable, which is precisely why it became popular as a generic.

Sourcing is trivial, generic globally for years, USP/EP reference standards are everywhere. Worth keeping in the catalog for completeness and for SERT-pharmacology research where the racemate is preferable to the single S-enantiomer. Clinically it's been largely superseded.

Evidence: 90
Mechanism: 90
Reliability: 82
Safety: 70
Sourcing: 92
Value: 88
Signal: 65
Staying power: 65

Plain-language summary Intrigue 60 / 100

Citalopram (Celexa) is a Danish-developed SSRI from H. Lundbeck, approved in Europe in 1989 and in the US in 1998. It is sold as a 50/50 mix of two mirror-image molecules; only one of those mirror images, the (S) form, actually does the serotonin-blocking work. The other is mostly inert and may even slow the active half down. That insight led Lundbeck to repackage the active half on its own as escitalopram. Citalopram is among the most selective SSRIs for serotonin over other targets, which gives it a clean side-effect profile but does carry a dose-dependent risk of QT interval prolongation on the heart tracing, prompting the FDA to cap the daily dose at 40 mg in 2011. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Selective serotonin reuptake inhibitor

A racemic phthalane SSRI; the most selective for SERT over NET in clinical use.

Abstract

Citalopram (1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile; CAS 59729-33-8; molecular formula C20H21FN2O; molecular weight 324.39) is a bicyclic phthalane SSRI developed at H. Lundbeck in Denmark and approved in Europe in 1989 and by the FDA in 1998 under the trade name Celexa. The compound is sold as the racemate; the (S)-enantiomer (escitalopram) accounts for essentially all SERT inhibitory activity, while the (R)-enantiomer is largely inactive but may attenuate the (S)-enantiomer's binding through allosteric SERT interaction. SERT affinity ((S)-enantiomer): Ki approximately 1 nM; selectivity over NET and DAT exceeds 1000-fold, making citalopram the most selective SSRI in clinical use. Plasma half-life is 33 to 37 hours; hepatic metabolism via CYP2C19, CYP3A4, and CYP2D6 produces minimally active metabolites. The compound is associated with dose-dependent QTc prolongation (FDA boxed warning issued 2011), with the maximum recommended dose reduced from 60 mg to 40 mg as a result. Used as the canonical selective SERT inhibitor in mechanism studies and as a reference compound in SSRI structure-activity work.

Mechanism of action

Selective high-affinity SERT inhibition; (S)-enantiomer is the active component. Racemic mixture; (R)-enantiomer is largely inactive with possible allosteric attenuation of (S) binding.

Reported research dose ranges

Reported research dose ranges in the literature.

References

Hyttel J. Citalopram: pharmacological profile of a specific serotonin uptake inhibitor with antidepressant activity. Prog Neuropsychopharmacol Biol Psychiatry 1982.
Sanchez C, Hyttel J. Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines. Cell Mol Neurobiol 1999.
Cooke MJ, Waring WS. Citalopram safety and risk of QT interval prolongation. Toxicol Rev 2013.

Read the full monograph

Available as a research-use-only PDF download. Note: PDFs for newly added compounds may take a few hours to propagate after this article was published.

KDC-MN-204

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

Citalopram

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs